The procurement decision by the Skandion Clinic (Skandionkliniken) in Uppsala, Sweden, has been reaffirmed following a competitor’s withdrawal of its second appeal. This means that the clinic will equip its proton therapy center with the C-RAD surface tracking solution.
The tender includes systems for four rooms in total with an option for two additional rooms and a long-term service contract. Now that all legal barriers have been removed, the only step remaining is the formal signing of the contract.
C-RAD has released a specific version of its Catalyst System for use in proton and particle therapy. Software and hardware are tailored for the application in this particular environment. In April 2015, C-RAD released the Universal Beam Triggering interface (UBTI), a beam-control interface that allows respiratory gated treatments on IBA proton therapy machines. This was an important functionality required by the Skandion Clinic.
The C-RAD’s Sentinel and Catalyst systems are characterized by a seamless integration into clinical environments. Interfaces to the treatment systems themselves and to existing radiation oncology information systems (ROIS) are essential to secure a smooth, secure and automated clinical workflow. As the Skandion Clinic is equipped with the MOSAIQ® ROIS, they considered this interface to be as essential, as the C-RAD solution could provide unique advantages.
The Skandion Clinic published its first tender in mid-2014. While it was decided in C-RAD’s favor, it was appealed by Uppsala-based Radiotherapy Equipment Scandinavia (Radeq), which distributes a competitive product. The tender was then relaunched and decided in C-RAD’s favor for the second time. The same competitor again filed an appeal, but withdrew it earlier this week. As a next step the purchasing agreement between the Skandion Clinic and C-RAD will be signed, which is expected to take place in the coming weeks.
“This first installation with the Skandion Clinic opens a new door into the fast-growing proton and particle therapy market,” says Tim Thurn, CEO of C-RAD. “There are additional projects coming up in the Nordic region as well the US in the next few years, and Asia is also a very rapidly developing proton and particle therapy market. The accuracy and workflow integration provided by the C‑RAD solution are tailored exactly to customers’ clinical needs. C-RAD is actively involved in other projects that are expected to be decided upon at the end of this year.”
About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 37. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).
